{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:23:13Z","timestamp":1771456993674,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.clon.2006.11.009","type":"journal-article","created":{"date-parts":[[2006,12,13]],"date-time":"2006-12-13T07:24:59Z","timestamp":1165994699000},"page":"38-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Use of Rituximab in Patients with Follicular Lymphoma"],"prefix":"10.1016","volume":"19","author":[{"given":"R.","family":"Marcus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2006.11.009_bib1","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin's lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0950-3536(96)80048-5","article-title":"Management of histologically indolent non-Hodgkin's lymphomas","volume":"9","author":"Solal-Celigny","year":"1996","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.clon.2006.11.009_bib3","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.1995.13.10.2656","article-title":"Coherent view of non-Hodgkin's lymphoma","volume":"13","author":"Aisenberg","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bmj.1.6112.533","article-title":"Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type","volume":"1","author":"Lister","year":"1978","journal-title":"Br Med J"},{"key":"10.1016\/j.clon.2006.11.009_bib5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood.V58.3.592.592","article-title":"The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomised trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation","volume":"58","author":"Hoppe","year":"1981","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.clon.2006.11.009_bib6","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1093\/annonc\/5.suppl_2.S67","article-title":"Chlorambucil\/prednisone vs CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden","volume":"5","author":"Kimby","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2003.05.128","article-title":"Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B","volume":"21","author":"Peterson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood.V47.5.747.747","article-title":"Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: preliminary results of a prospective trial","volume":"47","author":"Portlock","year":"1976","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib9","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","article-title":"Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial","volume":"16","author":"Solal-Celigny","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib10","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib11","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1023\/A:1008399623564","article-title":"High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol","volume":"11","author":"Brice","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib12","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High dose therapy followed by autologous purged stem cell transplantation and doxorubicin based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib13","first-page":"388a","article-title":"Long term results of the GELA study, R-CHOP vs CHOP in elderly patients with diffuse large B-cell lymphoma","volume":"104","author":"Coiffier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib14","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"Suppl 14","key":"10.1016\/j.clon.2006.11.009_bib15","first-page":"79","article-title":"Rituximab in indolent lymphoma: the single-agent pivotal trial","volume":"26","author":"McLaughlin","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib17","doi-asserted-by":"crossref","first-page":"169a","DOI":"10.1182\/blood.V104.11.585.585","article-title":"Single 4-dose rituximab treatment for low-tumor burden follicular lymphoma (FL): survival analyses with a follow-up (F\/Up) of at least 5 years","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib18","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","article-title":"Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib19","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2006.11.009_bib20","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.thj.6200559","article-title":"Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud","volume":"5","author":"Lemieux","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.clon.2006.11.009_bib22","doi-asserted-by":"crossref","first-page":"589s","DOI":"10.1200\/jco.2005.23.16_suppl.589","volume":"23","author":"Weide","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib23","first-page":"177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.clon.2006.11.009_bib24","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1046\/j.1365-2141.2001.03014.x","article-title":"Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone","volume":"114","author":"Di Gaetano","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clon.2006.11.009_bib25","first-page":"5137","volume":"61","author":"Alas","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.clon.2006.11.009_bib26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib27","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib28","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1200\/JCO.2005.05.004","article-title":"Rituximab plus short duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib29","first-page":"564","article-title":"Stage IV indolent lymphoma: a randomized study of concurrent vs sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance","volume":"22","author":"McLaughlin","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"10","key":"10.1016\/j.clon.2006.11.009_bib30","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib31","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib32","doi-asserted-by":"crossref","first-page":"106a","DOI":"10.1182\/blood.V106.11.350.350","article-title":"MabThera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III\/IV follicular non-Hodgkin s lymphoma (NHL): confirmed efficacy with longer follow-up","volume":"106","author":"Solal-Celigny","year":"2005","journal-title":"Blood"},{"issue":"Suppl 5","key":"10.1016\/j.clon.2006.11.009_bib33","first-page":"v51","article-title":"Rituximab plus mitoxantrone, chlorambucil, prednisolon (R-MCP) is superior to MCP alone in advanced indolent and follicular lymphoma \u2013 results of a phase III study (OSHO39)","volume":"16","author":"Herold","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib34","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"18S","key":"10.1016\/j.clon.2006.11.009_bib35","first-page":"424s","article-title":"Update of the FL2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma (FL) patients (pts)","volume":"24","author":"Foussard","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib36","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"Suppl 5","key":"10.1016\/j.clon.2006.11.009_bib37","first-page":"v109","article-title":"CVP plus rituximab compared to CVP alone in previously untreated patients with follicular lymphoma: impact of baseline prognostic factors","volume":"16","author":"Imrie","year":"2005","journal-title":"Ann\u00a0Oncol"},{"issue":"S2","key":"10.1016\/j.clon.2006.11.009_bib38","first-page":"274","article-title":"Q-TWiST analysis of rituximab plus CVP versus CVP alone as first-line treatment for advanced follicular lymphoma","volume":"90","author":"Cunningham","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clon.2006.11.009_bib39","first-page":"104a","article-title":"Combined immunochemotherapy (R-CHOP) significantly improves time to treatment failure in first-line therapy of follicular lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"102","author":"Hiddemann","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib40","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib41","doi-asserted-by":"crossref","first-page":"49a","DOI":"10.1182\/blood.V104.11.160.160","article-title":"Rituximab added to \u03b1IFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients","volume":"104","author":"Salles","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib42","doi-asserted-by":"crossref","first-page":"169a","DOI":"10.1182\/blood.V104.11.584.584","volume":"104","author":"Herold","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib43","doi-asserted-by":"crossref","first-page":"106A","DOI":"10.1182\/blood.V106.11.351.351","article-title":"Does combined immunochemotherapy with the monoclonal antibody Rituximab improve overall survival in the treatment of patients with indolent non-Hodgkin lymphoma? Preliminary results of a comprehensive meta-analysis","volume":"106","author":"Schulz","year":"2005","journal-title":"Blood"},{"issue":"Suppl 5","key":"10.1016\/j.clon.2006.11.009_bib44","first-page":"v52","article-title":"The role of rituximab maintenance treatment in relapsed follicular NHL: an interim analysis of the EORTC randomized intergroup trial","volume":"16","author":"Hagenbeek","year":"2005","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.clon.2006.11.009_bib45","first-page":"v110","volume":"16","author":"Dreyling","year":"2005","journal-title":"Ann Oncol"},{"issue":"18S","key":"10.1016\/j.clon.2006.11.009_bib46","first-page":"422s","volume":"24","author":"Dreyling","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib47","doi-asserted-by":"crossref","first-page":"558s","DOI":"10.1200\/jco.2004.22.90140.6502","article-title":"Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL)","volume":"22","author":"Hochster","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib48","doi-asserted-by":"crossref","first-page":"106a","DOI":"10.1182\/blood.V106.11.349.349","article-title":"Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B","volume":"106","author":"Hochster","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib49","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma \u2013 a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib50","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib51","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib52","doi-asserted-by":"crossref","first-page":"170a","DOI":"10.1182\/blood.V104.11.589.589","article-title":"Fc\u03b3 receptor polymorphisms do not influence progression free survival (PFS) of follicular NHL patients treated with CHOP followed by rituximab (SWOG 9800)","volume":"104","author":"Maloney","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib53","doi-asserted-by":"crossref","first-page":"170a","DOI":"10.1182\/blood.V104.11.590.590","article-title":"Evidence for FC\u03b3 receptorIIIA-independent rituximab effector mechanisms in patients with follicular lymphoma treated with combined immuno-chemotherapy","volume":"104","author":"Boettcher","year":"2004","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clon.2006.11.009_bib54","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1007\/s002800100312","article-title":"Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma","volume":"48","author":"Witzig","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clon.2006.11.009_bib55","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2006.11.009_bib56","doi-asserted-by":"crossref","first-page":"107a","DOI":"10.1182\/blood.V106.11.352.352","article-title":"An update of a phase II trial of CHOP followed by tositumomab\/iodine I-131 tositumomab (Bexxar\u00ae) for front-line treatment of advanced stage, follicular lymphoma: Southwest Oncology Group Protocol 9911","volume":"106","author":"Press","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib57","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib58","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2006-04-020057","article-title":"Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab","author":"Bowles","year":"2006","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.clon.2006.11.009_bib59","first-page":"85","article-title":"Rituximab as single agent and in combination with interferon-\u03b1-2a as treatment of untreated and first relapse follicular or other low-grade lymphomas. A randomized phase II study","volume":"13","author":"Kimby","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib60","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2006.11.009_bib61","doi-asserted-by":"crossref","first-page":"765a","DOI":"10.1182\/blood.V104.11.2798.2798","article-title":"Treatment of B-CLL cells with bortezomib and rituximab reduces cell viability in vitro","volume":"104","author":"Lewintre","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib62","doi-asserted-by":"crossref","first-page":"686a","DOI":"10.1182\/blood.V106.11.2441.2441","article-title":"BiovaxID\u2122 vaccine therapy of follicular lymphoma in first remission: long-term follow-up of a phase II trial and status of a controlled, randomized phase III trial","volume":"106","author":"Santos","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clon.2006.11.009_bib63","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2006.11.009_bib64","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655506004237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655506004237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:31:30Z","timestamp":1760542290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655506004237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0936655506004237"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2006.11.009","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Rituximab in Patients with Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2006.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}